Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K was filed by Galecto, Inc. on February 9, 2022, reporting an event effective February 3, 2022. The filing concerns corporate governance and director compensation. The request metadata identifies Damora Therapeutics, Inc., but the filing itself identifies the registrant as Galecto, Inc. (Nasdaq: GLTO).

Financial Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.

Material Changes

  • The Board established a Research and Development Committee effective February 3, 2022.
  • The Company amended its Non-Employee Director Compensation Policy to add annual retainers for the committee.
  • Each R&D Committee member will receive $7,500 annually; the committee Chair will receive an additional $7,500 annually.
  • The non-executive Board Chair will receive an annual option to purchase 36,000 shares on each annual meeting date.
  • Other non-employee directors will continue to receive annual options to purchase 18,000 shares each.

Guidance, Outlook, Risks, and Unusual Items

The filing provides no financial guidance, business outlook, risk update, contingencies, or unusual operating items. The primary disclosed effect is the potential compensation expense and equity dilution associated with director retainers and stock options; the filing does not provide a valuation, exercise price, vesting terms, or estimated expense for the options.

Investor Verification Points

  • Verify that the applicable registrant is Galecto, Inc., not Damora Therapeutics, Inc.
  • Review Exhibit 10.1 for the complete terms of the amended director compensation policy.
  • Assess the eventual accounting expense and potential dilution from the annual director option awards.
  • Confirm the composition, responsibilities, and Chair of the newly established R&D Committee in subsequent filings.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.